PT  - JOURNAL ARTICLE
AU  - Fakhroo, Aisha D.
AU  - Nasarallah, Gheyath K.
AU  - Khan, Taushif
AU  - Cyprian, Farhan S.
AU  - Ali, Fatima Al
AU  - Ata, Manar M.A.
AU  - Taleb, Sara
AU  - Hssain, Ali A.
AU  - Eid, Ali H.
AU  - Abu-Raddad, Laith J.
AU  - Al-Khal, Abdullatif
AU  - Thani, Asmaa A. Al
AU  - Marr, Nico
AU  - Yassine, Hadi M.
TI  - Detection of autoimmune antibodies in severe but not in moderate or asymptomatic COVID-19 patients
AID  - 10.1101/2021.03.02.21252438
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.02.21252438
4099  - http://medrxiv.org/content/early/2021/03/10/2021.03.02.21252438.short
4100  - http://medrxiv.org/content/early/2021/03/10/2021.03.02.21252438.full
AB  - The heterogeneity of COVID-19 lies within its diverse symptoms and severity, ranging from mild to lethal. Acute respiratory distress syndrome (ARDS) has been shown to be the leading cause of mortality in COVID-19 patients, characterized by a hyper cytokine storm. Autoimmunity is proposed to occur as a result of COVID-19, given the high similarity of the immune responses observed in COVID-19 and autoimmune diseases. Here, we investigate the level of autoimmune antibodies in COVID-19 patients with different severities. Initial screening for antinuclear antibodies (ANA) IgG revealed that 1.6% (2/126) and 4% (5/126) of ICU COVID-19 cases developed strong and moderate ANA levels, respectively. However, all the non-ICU cases (n=273) were ANA negative. The high ANA level was confirmed by immunofluorescence (IFA) and large-scale autoantibody screening by phage immunoprecipitation-sequencing (PhIP-Seq). Indeed, the majority of the samples showed “speckled” ANA pattern by microscopy, and we demonstrate that samples of ICU patients with strong and moderate ANA levels contain autoantibody specificities that predominantly targeted proteins involved in intracellular signal transduction, metabolism, apoptotic processes, and cell death; further denoting reactivity to nuclear and cytoplasmic antigens. In conclusion, our results further support the notion of routine screening for autoimmune responses in COVID-19 patients, which might help improve disease prognosis and patient management. Further, results provide compelling evidence that ANA-positive individuals should be excluded from being donors for convalescent plasma therapy in the context of Covid-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported with funding from Qatar National Research Funds (QNRF), grant #NPRP11S-1212-170092, and funding from Sidra Medicine (SDR400048).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval This study was approved by IRB committees of Hamad Medical Corporation (MRC-01-20-145), Sidra Medicine (IRB Protocol #: 1511001953) and Qatar University (QU-IRB 1289-EA/20)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon a direct request from the corresponding author.